NCT02113527

Brief Summary

Rome III criteria defined functional dyspepsia (FD) as the presence of symptoms from the gastroduodenal region in the absence of any organic, systemic or metabolic disease that is likely to explain the symptoms. FD can be further subdivided into two diagnostic categories: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Disorders of gastric electric activity and abnormal gastric emptying are probably actively involved in the FD onset. Different noninvasive procedures may be applied in order to evaluate the gastric motor functions such as 13C breath testing and cutaneous electrogastrography. Besides, different gastrointestinal peptides (i.e. CCK, peptide YY, Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II) are involved in the control of gastroduodenal motility. Aims of the present study are: 1) to evaluate the GI peptide circulating concentrations, the gastric electrical activity and gastric emptying time by applying noninvasive procedures in patients suffering from functional dyspepsia and 2) to test whether a significant difference exists between the two diagnostic categories of meal-induced dyspeptic symptoms

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 26, 2014

Completed
6 days until next milestone

Study Start

First participant enrolled

April 1, 2014

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 14, 2014

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2014

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

September 2, 2015

Status Verified

September 1, 2015

Enrollment Period

7 months

First QC Date

March 26, 2014

Last Update Submit

September 1, 2015

Conditions

Keywords

ElectrogastrographyFunctional dyspepsiaGastric emptyingGastrointestinal peptidesRome III criteria

Outcome Measures

Primary Outcomes (1)

  • Fasting plasma concentration of GI peptides, gastric emptying time and dyspepsia subtype.

    Exploration of relationships between GI peptide concentrations (CCK, peptide YY, Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II), solid gastric emptying, and dyspepsia subtype. Blood samples will be compared pre/post test meal for FD cohorts (EPS/PDS) and controls: 0 time/baseline and 16 times/post meal. Associations of plasma GI peptides pre and postprandial levels \& gastric emptying will be studied. Amount of 13CO2 will be determined for each time point (1 pre/ 16 post meal) using equation nested in software package with IRMS. The concentration of 13CO2 and 12CO2 in the exhaled breath samples will be measured by mass spectrometry.

    Duration of 4-hour study visit

Secondary Outcomes (1)

  • Gastric electrical activity and GI peptides according functional dyspepsia subtype

    Duration of 4-hour study visit

Study Arms (3)

Epigastric pain syndrome (EPS)

Patients suffering from functional dyspepsia characterized by epigastric pain syndrome according to Rome III criteria

Postprandial distress syndrome (PDS)

Patients suffering from functional dyspepsia characterized by postprandial distress syndrome according to Rome III criteria

Healthy subjects

Healthy subjects as control group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients will be recruited in this observational study from the out-patients of the National Institute of Digestive Diseases, I.R.C.C.S. Saverio de Bellis, Castellana Grotte, Bari, Italy.

You may qualify if:

  • Patients suffering from dyspeptic symptoms according to Rome III;
  • Helicobacter pylori negative subjects;
  • age 19-70 yr.;
  • willingness to complete the study;
  • not recent administration (in the 2 months before the examination) of anti-inflammatory drugs (NSAIDs), antibiotics, bismuth, antacids, H2-receptor antagonists, proton pump inhibitor, sucralfate or misoprostol;
  • at least one endoscopic/radiological GI evaluation in the last 5 yrs.

You may not qualify if:

  • previous history of gastric tumors or gastric surgery
  • lactose intolerance;
  • celiac disease, wheat sensitivity;
  • alarm symptoms (GI bleeding, weight loose etc.);
  • psychiatric diseases;
  • familial history of peptic ulcer;
  • gastric cancer or IBD;
  • abnormal thyroid function;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institute of Digestive Diseases IRCCS "Saverio de Bellis"

Castellana Grotte, Bari, 70013, Italy

Location

Related Publications (5)

  • Chasen M, Bhargava R. Gastrointestinal symptoms, electrogastrography, inflammatory markers, and PG-SGA in patients with advanced cancer. Support Care Cancer. 2012 Jun;20(6):1283-90. doi: 10.1007/s00520-011-1215-8. Epub 2011 Jun 19.

    PMID: 21688162BACKGROUND
  • Miwa H, Watari J, Fukui H, Oshima T, Tomita T. [Pathogenesis and management of functional dyspepsia]. Nihon Rinsho. 2010 Jul;68(7):1391-401. Japanese.

    PMID: 20662226BACKGROUND
  • Khoo J, Rayner CK, Feinle-Bisset C, Jones KL, Horowitz M. Gastrointestinal hormonal dysfunction in gastroparesis and functional dyspepsia. Neurogastroenterol Motil. 2010 Dec;22(12):1270-8. doi: 10.1111/j.1365-2982.2010.01609.x. Epub 2010 Oct 5.

    PMID: 20939851BACKGROUND
  • De Smet B, Mitselos A, Depoortere I. Motilin and ghrelin as prokinetic drug targets. Pharmacol Ther. 2009 Aug;123(2):207-23. doi: 10.1016/j.pharmthera.2009.04.004. Epub 2009 May 6.

    PMID: 19427331BACKGROUND
  • Geeraerts B, Mimidis K, van Oudenhove L, Vos R, Karamanolis G, Tack J. Role of endogenous opioids in the control of gastric sensorimotor function. Neurogastroenterol Motil. 2008 Oct;20(10):1094-102. doi: 10.1111/j.1365-2982.2008.01144.x. Epub 2008 May 15.

    PMID: 18482249BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

breath specimen, whole blood, serum, white cells.

MeSH Terms

Conditions

Dyspepsia

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Francesco Russo, MD

    IRCCS "S. de Bellis"

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior researcher

Study Record Dates

First Submitted

March 26, 2014

First Posted

April 14, 2014

Study Start

April 1, 2014

Primary Completion

November 1, 2014

Study Completion

June 1, 2015

Last Updated

September 2, 2015

Record last verified: 2015-09

Locations